IL1B and type 2 diabetes mellitus: Clinical trials using IL-1β inhibitors, such as anakinra, canakinumab, and Xoma 052, have shown promising results in improving glycemic control and beta cell function in patients with T2D (119, 137, 157, 158), ClinicalTrials.gov identifier: NCT00303394 (159), ClinicalTrials.gov identifier: NCT01327846 (160, 161).